Section 4 of 6
Clinical evidence
267 evidence topics · 28 sources
Study summaries
PROGRESS
Objective
Objective of the Cohort 1 interim analysis
Location and study date
Study status and dates
| Registry field | Quoted record |
|---|---|
| Sponsor | “Incyte Corporation” |
| Sponsor protocol number | “INCB 00928-201” |
| Overall status | “Recruiting” |
| Start date, actual | “2022-05-05” |
| Primary completion, estimated | “2027-07-30” |
| Completion, estimated | “2033-01-20” |
| Enrollment, estimated (all cohorts) | “98” |
Registered study sites
Sponsor and congress presentation of Cohort 1 results
Posted results
No evidence found.
Study design
Randomized, double-blind, placebo-controlled period followed by an open-label extension
Registry design fields
| Design field | Quoted record |
|---|---|
| Phase | “Phase 2” |
| Allocation | “Randomized” |
| Intervention model | “Parallel” |
| Masking | “Double” |
| Primary purpose | “Treatment” |
Three age cohorts
Blinding during the first 24 weeks and crossover to open-label treatment
Eligibility criteria
Inclusion criteria stated in the prescribing information
ACVR1 variants eligible for enrollment
Treatment
Concomitant and rescue medications for flare-ups
No evidence found.
Study outcomes
Rationale for using total new heterotopic ossification volume on low-dose whole-body CT as the label efficacy endpoint
Label efficacy endpoint: total new HO lesion volume on whole-body CT
Protocol-specified primary endpoint: occurrence of new HO lesions at Week 24
Registered secondary endpoints of the double-blind period
Registered open-label extension endpoints at Week 48
Expert recommendation for volumetric low-dose CT measurement of HO in FOP trials
Natural history rate of new HO accrual on low-dose whole-body CT
“The mean annualized volume of new HO was 23.6 × 103 mm3/year; highest at 8 to <15 and 15 to <25 years (21.9 × 103 and 41.5 × 103 mm3/year, respectively) and lowest at 25 to 65 years (4.6 × 103 mm3/year).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Results from individuals receiving standard care for up to 3 years in this natural history study show the debilitating effect and progressive nature of FOP cross-sectionally and longitudinally, with greatest progression during childhood and early adulthood.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Flare-up endpoint based on a patient-reported instrument
Statistical analysis description
Number of participants (Planned and analyzed)
Planned Cohort 1 enrollment
Description of analysis sets
Denominators reported for the Week 24 primary endpoint
Formal definitions of analysis populations
No evidence found.
Results
Participant disposition
Randomization and completion of the double-blind period
Entry into the open-label extension
Baseline characteristics
Demographics and baseline characteristics by arm
| Characteristic | Zilurgisertib 100 mg (n=32) | Placebo (n=31) |
|---|---|---|
| Age, mean (SD), y | “20.5 (11.7)” | “22.0 (11.0)” |
| Male, n (%) | “17 (53.1)” | “14 (45.2)” |
| Race, White, n (%) | “17 (53.1)” | “18 (58.1)” |
| Race, Asian, n (%) | “8 (25.0)” | “10 (32.3)” |
| Race, Black, n (%) | “2 (6.3)” | “1 (3.2)” |
| Race, Multiracial, n (%) | “1 (3.1)” | “0” |
| Time since initial diagnosis, mean (SD), y | “12.6 (9.9)” | “13.2 (9.1)” |
| Baseline CAJIS score <18, n (%) | “27 (84.4)” | “26 (83.9)” |
| Baseline CAJIS score 18-23, n (%) | “5 (15.6)” | “5 (16.1)” |
| Time since last flare-up, mean (SD), y | “0.7 (0.6)” | “0.4 (0.2)” |
| Last flare-up location, upper back, n (%) | “4 (12.5)” | “5 (16.1)” |
| Last flare-up location, lower back, n (%) | “4 (12.5)” | “5 (16.1)” |
| Last flare-up location, right hip, n (%) | “4 (12.5)” | “4 (12.9)” |
| Last flare-up location, right leg, n (%) | “2 (6.3)” | “4 (12.9)” |
| Total volume of HO lesions at baseline, median (range), cm3 | “270.0 (21.3–1140.1)” | “265.6 (5.7–1672.0)” |
Missing race data
Efficacy results
Summary: label endpoint and protocol primary endpoint
The protocol-specified primary endpoint, the proportion of participants with new HO lesions at Week 24, occurred in 1 of 32 participants (3.1%) receiving zilurgisertib and 5 of 30 participants (16.7%) receiving placebo (P=0.0986), a difference that did not reach statistical significance. The prescribing information establishes efficacy on a different measure, total new HO lesion volume on whole-body CT excluding the head, defined to include expansion of baseline lesions and new discrete HO: the mean change from baseline at Week 24 was −3.2 cm³ (SD 19.9) with zilurgisertib and +24.6 cm³ (SD 51.9) with placebo, a Hodges-Lehmann treatment difference of −15.8 cm³ (95% CI −32.1 to −6.0). The congress poster and the results press release report the volume of new lesions (mean 0.003 cm³ vs 6.57 cm³; nominal P<0.0001) and the change in total lesion volume (mean −3.24 cm³ vs 24.64 cm³; nominal P=0.004) as separate secondary endpoints. Through Week 48, no participant in either original arm had new HO lesions on whole-body CT (n=61).
Label endpoint: total new HO lesion volume at Week 24
Protocol primary endpoint: proportion of participants with new HO lesions at Week 24
Secondary endpoint: number of new HO lesions at Week 24
Secondary endpoint: volume of new HO lesions at Week 24
Secondary endpoint: change in total volume of all HO lesions at Week 24
Secondary endpoint: annualized new flare-ups through Week 24
Open-label extension through Week 48: new HO lesions
Open-label extension through Week 48: total HO lesion volume and flare-ups
Investigator interpretation of the Week 24 and Week 48 results
Health-related quality of life and patient-reported outcomes
Flare-up results in the plain language summary
Physical function and health-related quality of life
No evidence found.
Safety results
Adverse reactions in fewer than 10% of participants
Treatment-emergent adverse events during the 24-week placebo-controlled period
| Event | Zilurgisertib 100 mg (n=32), n (%) | Placebo (n=31), n (%) |
|---|---|---|
| Any TEAE | “29 (90.6)” | “30 (96.8)” |
| Treatment-related TEAE | “15 (46.9)” | “11 (35.5)” |
| Serious TEAE | “2 (6.3)” | “3 (9.7)” |
| Grade ≥3 TEAE | “2 (6.3)” | “4 (12.9)” |
| Fatal adverse event | “0” | “0” |
| Treatment-related serious TEAE | “1 (3.1)” | “0” |
| TEAE leading to dose interruption | “2 (6.3)” | “1 (3.2)” |
| TEAE leading to dose reduction or withdrawal | “0” | “0” |
| FOP flare-up or aching/pain due to FOP | “8 (25.0)” | “17 (54.8)” |
| Headache | “7 (21.9)” | “5 (16.1)” |
| Upper respiratory tract infection | “7 (21.9)” | “3 (9.7)” |
| Arthralgia | “6 (18.8)” | “1 (3.2)” |
| Epistaxis | “4 (12.5)” | “0” |
| Nausea | “4 (12.5)” | “1 (3.2)” |
Severity, discontinuations, and consistency between adults and adolescents
Study limitations
Summary: limitations of the PROGRESS Cohort 1 evidence
PROGRESS is a phase 2 trial in which 63 participants were randomized, with a placebo-controlled period of 24 weeks; data after Week 24 come from an open-label extension in which all participants received zilurgisertib, and the Week 48 analysis is reported as interim. The protocol-specified primary endpoint (new HO lesions in 1 of 32 vs 5 of 30 participants; P=0.0986) did not reach statistical significance, and approval rests on a secondary volumetric measure; the poster and results press release label the P values for secondary endpoints as nominal. Endpoint nomenclature differs across sources: the prescribing information reports "total new HO volume" (mean change −3.2 cm³ [SD 19.9] vs +24.6 cm³ [SD 51.9]), while the poster and results press release report "change in total lesion volume" with means and standard deviations (−3.24 [19.86] vs 24.64 [51.94]) that round to the label's values, and report a separate "new lesion volume" endpoint. The standard deviation for new lesion volume in the placebo arm is 20.70 in the poster and results press release and 20.71 in the congress abstract. The label's adverse reaction table and the poster's adverse event table report different arthralgia counts (7 [22%] vs 3 [10%] in the label; 6 [18.8%] vs 1 [3.2%] in the poster). No results are posted on ClinicalTrials.gov and no peer-reviewed publication of PROGRESS was identified; analysis-set definitions, the statistical analysis plan, and the multiplicity procedure are not public. Efficacy has not been established in participants younger than 12 years, and too few participants aged 65 years and older were enrolled to assess response in that group.
Primary endpoint not statistically significant
Interim analysis with an uncontrolled extension period
Age groups without established efficacy
LIMBER-104
Objective
Registered objective: safety, pharmacokinetics, pharmacodynamics, and efficacy in anemia due to myelofibrosis
Location and study date
Study identifiers, dates, and status: registry record
| Field | Registry record |
|---|---|
| Sponsor protocol number | “INCB 00928-104” |
| EudraCT number | “2020-004029-21” |
| Study start (actual) | “2021-03-19” |
| Primary completion (actual) | “2025-04-01” |
| Study completion (estimated) | “2027-11-26” |
| Enrollment (actual) | “84” |
| Overall status | “Active, not recruiting” |
| Results first posted | “2026-05-12” |
Study design
Registered design details
| Design feature | Registry record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Sequential Assignment” |
| Masking | “None (Open Label)” |
Three treatment groups: monotherapy, add-on to ruxolitinib, and ruxolitinib-naive combination
Dose-escalation algorithm
Eligibility criteria
Anemia and transfusion-dependence definitions
Treatment group-specific criteria
Age, risk category, and key exclusions
| Criterion | Registry record |
|---|---|
| Ages eligible | “18 Years and older” |
| Life expectancy | “Life expectancy is greater than 6 months” |
| Transplant exclusion | “Undergone any prior allogenic or autologous stem cell transplantation or a candidate for such transplantation.” |
Treatment
Starting doses and dose range
Dose levels administered and treatment duration
Study outcomes
Rationale for using treatment-emergent adverse events and dose-limiting toxicities as the primary endpoints
Registered primary outcome measures
Dose-limiting toxicity and maximum tolerated dose definitions
Rationale for dose-finding in three populations
Mechanistic rationale: hepcidin as the pharmacodynamic target
Secondary endpoints: anemia response, pharmacokinetics, and pharmacodynamics
Statistical analysis description
Number of participants (Planned and analyzed)
Planned dose-escalation sample size
Planned expansion sample size, withdrawn by amendment
Participants enrolled and analyzed
Description of analysis sets
Full analysis set and safety population
Results
Participant disposition
Participant flow by dose group, posted results
| Group | Started | Completed | Death | Sponsor decision | Physician decision | Withdrawal by subject | Ongoing |
|---|---|---|---|---|---|---|---|
| Monotherapy 50 mg once daily | “4” | “0” | “2” | “0” | “1” | “0” | “1” |
| Monotherapy 100 mg once daily | “4” | “2” | “0” | “0” | “0” | “1” | “0” |
| Monotherapy 200 mg once daily | “6” | “0” | “2” | “1” | “1” | “1” | “0” |
| Monotherapy 400 mg once daily | “11” | “4” | “2” | “2” | “0” | “1” | “2” |
| Monotherapy 600 mg once daily | “4” | “3” | “0” | “0” | “0” | “1” | “0” |
| Monotherapy 300 mg twice daily | “3” | “1” | “1” | “0” | “1” | “0” | “0” |
| Add-on 100 mg once daily + ruxolitinib | “4” | “1” | “2” | “0” | “1” | “0” | “0” |
| Add-on 200 mg once daily + ruxolitinib | “8” | “1” | “1” | “1” | “1” | “2” | “2” |
| Add-on 400 mg once daily + ruxolitinib | “12” | “3” | “4” | “3” | “0” | “2” | “0” |
| Add-on 600 mg once daily + ruxolitinib | “7” | “0” | “1” | “4” | “1” | “1” | “0” |
| Add-on 300 mg twice daily + ruxolitinib | “6” | “0” | “1” | “3” | “1” | “0” | “0” |
| JAK inhibitor-naive 400 mg once daily + ruxolitinib | “7” | “1” | “0” | “4” | “1” | “0” | “0” |
| JAK inhibitor-naive 300 mg twice daily + ruxolitinib | “8” | “0” | “0” | “5” | “2” | “1” | “0” |
Baseline characteristics
Age and baseline hemoglobin by treatment group, final analysis
Transfusion dependence and baseline hepcidin, interim analysis
Efficacy results
Anemia response at Weeks 24 and 48
Duration of anemia response, posted results
| Group | Participants analyzed | Median duration (days) |
|---|---|---|
| Monotherapy 200 mg once daily, non-transfusion dependent at baseline | “1 participants” | “429” |
| Monotherapy 400 mg once daily, non-transfusion dependent at baseline | “1 participants” | “182” |
| Add-on 100 mg once daily + ruxolitinib, non-transfusion dependent at baseline | “1 participants” | “691” |
Percentage change in hepcidin from Cycle 1 Day 15 to Cycle 7 Day 1, posted results
| Group | Participants analyzed | Mean percent change | Standard deviation |
|---|---|---|---|
| Monotherapy 50 mg once daily | “4” | “-38.50” | “32.98” |
| Monotherapy 100 mg once daily | “4” | “-30.46” | “28.81” |
| Monotherapy 200 mg once daily | “6” | “-10.13” | “62.13” |
| Monotherapy 400 mg once daily | “8” | “-30.57” | “50.8” |
| Monotherapy 600 mg once daily | “4” | “-39.36” | “34.4” |
| Monotherapy 300 mg twice daily | “3” | “-54.89” | “40.6” |
| Add-on 100 mg once daily + ruxolitinib | “4” | “6.08” | “69.09” |
| Add-on 200 mg once daily + ruxolitinib | “8” | “-44.31” | “33.37” |
| Add-on 400 mg once daily + ruxolitinib | “11” | “-42.44” | “48.87” |
| Add-on 600 mg once daily + ruxolitinib | “7” | “-54.71” | “35.36” |
| Add-on 300 mg twice daily + ruxolitinib | “5” | “-45.43” | “54.41” |
| JAK inhibitor-naive 400 mg once daily + ruxolitinib | “7” | “56.26” | “116.2” |
| JAK inhibitor-naive 300 mg twice daily + ruxolitinib | “7” | “-58.00” | “39.01” |
Spleen, response, and survival endpoints not analyzed
Pharmacokinetics at steady state, interim analysis
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Dose-limiting toxicities and maximum tolerated dose, final analysis
Maximum tolerated dose not determined, posted results
Primary safety outcomes by dose group, posted results
| Group | Any TEAE | Any grade 3 or higher TEAE and any treatment-emergent SAE | DLT-evaluable participants | Participants with DLTs |
|---|---|---|---|---|
| Monotherapy 50 mg once daily | “4” | “1” | “4” | “0” |
| Monotherapy 100 mg once daily | “4” | “0” | “3” | “0” |
| Monotherapy 200 mg once daily | “6” | “5” | “3” | “0” |
| Monotherapy 400 mg once daily | “11” | “3” | “3” | “0” |
| Monotherapy 600 mg once daily | “4” | “2” | “4” | “0” |
| Monotherapy 300 mg twice daily | “3” | “2” | “2” | “0” |
| Add-on 100 mg once daily + ruxolitinib | “4” | “3” | “4” | “0” |
| Add-on 200 mg once daily + ruxolitinib | “8” | “5” | “4” | “0” |
| Add-on 400 mg once daily + ruxolitinib | “12” | “6” | “3” | “0” |
| Add-on 600 mg once daily + ruxolitinib | “7” | “6” | “7” | “0” |
| Add-on 300 mg twice daily + ruxolitinib | “6” | “3” | “4” | “1” |
| JAK inhibitor-naive 400 mg once daily + ruxolitinib | “7” | “6” | “7” | “0” |
| JAK inhibitor-naive 300 mg twice daily + ruxolitinib | “8” | “6” | “3” | “0” |
Serious adverse events and all-cause mortality by dose group, posted results
| Group | Serious adverse events, affected/at risk (%) | All-cause mortality, affected/at risk (%) |
|---|---|---|
| Monotherapy 50 mg once daily | “1/4 (25.00%)” | “2/4 (50.00%)” |
| Monotherapy 100 mg once daily | “0/4 (0.00%)” | “0/4 (0.00%)” |
| Monotherapy 200 mg once daily | “4/6 (66.67%)” | “2/6 (33.33%)” |
| Monotherapy 400 mg once daily | “3/11 (27.27%)” | “2/11 (18.18%)” |
| Monotherapy 600 mg once daily | “1/4 (25.00%)” | “0/4 (0.00%)” |
| Monotherapy 300 mg twice daily | “2/3 (66.67%)” | “1/3 (33.33%)” |
| Add-on 100 mg once daily + ruxolitinib | “3/4 (75.00%)” | “2/4 (50.00%)” |
| Add-on 200 mg once daily + ruxolitinib | “3/8 (37.50%)” | “1/8 (12.50%)” |
| Add-on 400 mg once daily + ruxolitinib | “6/12 (50.00%)” | “4/12 (33.33%)” |
| Add-on 600 mg once daily + ruxolitinib | “4/7 (57.14%)” | “1/7 (14.29%)” |
| Add-on 300 mg twice daily + ruxolitinib | “1/6 (16.67%)” | “1/6 (16.67%)” |
| JAK inhibitor-naive 400 mg once daily + ruxolitinib | “3/7 (42.86%)” | “0/7 (0.00%)” |
| JAK inhibitor-naive 300 mg twice daily + ruxolitinib | “2/8 (25.00%)” | “0/8 (0.00%)” |
| Total | “33/84 (39.29%)” | “16/84 (19.05%)” |
Most frequent serious adverse events, all 84 participants
| Serious adverse event | Affected/at risk (%) |
|---|---|
| Pneumonia | “7/84 (8.33%)” |
| Sepsis | “3/84 (3.57%)” |
| Atrial fibrillation | “3/84 (3.57%)” |
| Acute kidney injury | “3/84 (3.57%)” |
| Squamous cell carcinoma of skin | “3/84 (3.57%)” |
Nonserious adverse events in 10% or more of all 84 participants, and events listed in the FOP label
| Adverse event | Affected/at risk (%) |
|---|---|
| Diarrhoea | “24/84 (28.57%)” |
| Nausea | “18/84 (21.43%)” |
| Alopecia | “17/84 (20.24%)” |
| Oedema peripheral | “15/84 (17.86%)” |
| Thrombocytopenia | “14/84 (16.67%)” |
| Fatigue | “14/84 (16.67%)” |
| Dyspnoea | “14/84 (16.67%)” |
| Epistaxis | “13/84 (15.48%)” |
| Hyperuricaemia | “12/84 (14.29%)” |
| Cough | “12/84 (14.29%)” |
| Blood creatinine increased | “11/84 (13.10%)” |
| Anaemia | “11/84 (13.10%)” |
| Urinary tract infection | “10/84 (11.90%)” |
| Pruritus | “10/84 (11.90%)” |
| Hyperkalaemia | “10/84 (11.90%)” |
| Neutropenia | “9/84 (10.71%)” |
| Headache | “7/84 (8.33%)” |
| Rash | “6/84 (7.14%)” |
| Arthralgia | “4/84 (4.76%)” |
| Upper respiratory tract infection | “4/84 (4.76%)” |
| Iron overload | “1/84 (1.19%)” |
Grade 3 or higher adverse events, interim analysis
Study limitations
Summary: limitations for a formulary review of zilurgisertib in fibrodysplasia ossificans progressiva
LIMBER-104 is an open-label, nonrandomized dose-escalation study without a control group, so adverse events cannot be attributed to zilurgisertib apart from myelofibrosis, ruxolitinib, and age-related comorbidity. The population differs from the FOP population in the label: the mean age of the 84 participants was 72.0 years, and all had myelofibrosis with anemia. Daily zilurgisertib doses ranged from 50 mg to 600 mg, and 52 of 84 participants (62%) received ruxolitinib concurrently. The planned expansion stage (Phase 2) was not conducted after enrollment was closed by sponsor decision, so the maximum tolerated dose and the recommended dose for expansion were not established, and spleen, response, and survival endpoints were not analyzed.
The two public sources differ on several counts. The final congress abstract reports 3 participants with dose-limiting toxicities in the add-on group, while the posted registry results report 1 dose-limiting toxicity among DLT-evaluable participants. Group sizes also differ (32, 38, and 14 participants in the abstract; 32, 37, and 15 in the registry safety population, which assigns participants by the treatment actually received). The abstract reports fatal treatment-emergent adverse events in 3 participants, while the registry reports all-cause mortality of 16 of 84 participants (19.05%) over a collection period of up to 1,560 days. No full peer-reviewed publication was identified, and no health-related quality of life or patient-reported outcome results were reported.
Investigator conclusion on anemia efficacy
INCB 00928-105
Objective
Registered objective: safety, pharmacokinetics, pharmacodynamics, and efficacy in anemia due to MDS or multiple myeloma
Location and study date
Study identifiers, dates, and status: registry record
| Field | Registry record |
|---|---|
| Acronym | “LIMBER” |
| Sponsor protocol number | “INCB 00928-105” |
| EudraCT number | “2020-002771-35” |
| Study start (actual) | “2021-08-19” |
| Primary completion (actual) | “2024-08-15” |
| Study completion (actual) | “2024-08-15” |
| Enrollment (actual) | “22” |
| Overall status | “Terminated” |
| Reason stopped | “Strategic Business Decision” |
| Results first posted | “2025-10-22” |
Study design
Registered design details
| Design feature | Registry record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “N/A” |
| Interventional model | “Sequential Assignment” |
| Masking | “None (Open Label)” |
Planned dose-escalation and expansion stages
Eligibility criteria
Inclusion criteria
Exclusion criteria relevant to safety interpretation
Treatment
Dose levels and treatment duration, posted results
| Group as posted | Registry record |
|---|---|
| Dose levels | “Zilurgisertib 50 mg QD”; “Zilurgisertib 100 mg QD”; “Zilurgisertib 200 mg QD”; “Zilurgisertib 400 mg QD”; “Zilurgisertib 600 mg QD” |
Study outcomes
Rationale for using treatment-emergent adverse events and dose-limiting toxicities as the primary endpoints
Registered primary outcome measures
Dose-limiting toxicity and maximum tolerated dose definitions
Secondary endpoints: anemia response and transfusion independence
Statistical analysis description
Number of participants (Planned and analyzed)
Participants enrolled and analyzed
| Measure | Registry record |
|---|---|
| Enrollment (actual) | “22” |
| Overall number of baseline participants | “21” |
| Participants with multiple myeloma | “No participants with MM were enrolled.” |
Description of analysis sets
Full analysis set and DLT-evaluable population
Results
Participant disposition
Participant flow by dose group, posted results
| Group | Started | Completed | Death | Lost to follow-up | Study terminated by sponsor | Physician decision | Withdrawal by subject | Started new therapy |
|---|---|---|---|---|---|---|---|---|
| 50 mg once daily | “4” | “0” | “1” | “1” | “1” | “0” | “1” | “0” |
| 100 mg once daily | “5” | “0” | “1” | “0” | “3” | “1” | “0” | “0” |
| 200 mg once daily | “4” | “0” | “0” | “0” | “2” | “0” | “2” | “0” |
| 400 mg once daily | “5” | “0” | “1” | “0” | “2” | “0” | “1” | “1” |
| 600 mg once daily | “3” | “0” | “0” | “0” | “3” | “0” | “0” | “0” |
Baseline characteristics
Efficacy results
Anemia response and transfusion independence, posted results
| Group | Anemia response: participants analyzed | Anemia response (%) | Anemia response 95% CI | Transfusion independence: participants analyzed | Transfusion independence (%) | Transfusion independence 95% CI |
|---|---|---|---|---|---|---|
| 50 mg once daily | “2” | “0.0” | “(0.0 to 84.2)” | “2” | “0.0” | “(0.0 to 84.2)” |
| 100 mg once daily | “4” | “0.0” | “(0.0 to 60.2)” | “1” | “100.0” | “(2.5 to 100.0)” |
| 200 mg once daily | “2” | “0.0” | “(0.0 to 84.2)” | “2” | “0.0” | “(0.0 to 84.2)” |
| 400 mg once daily | “4” | “0.0” | “(0.0 to 60.2)” | “1” | “0.0” | “(0.0 to 97.5)” |
| 600 mg once daily | “2” | “0.0” | “(0.0 to 84.2)” | “1” | “0.0” | “(0.0 to 97.5)” |
Largest increase in hemoglobin over any rolling 8-week period and transfusion rate, posted results
| Group | Hemoglobin: participants analyzed | Largest mean hemoglobin increase (g/L) | Standard deviation | Transfusion rate, Weeks 12 to 24 (RBC units per participant-month) | Standard deviation |
|---|---|---|---|---|---|
| 50 mg once daily | “3” | “2.19” | “2.782” | “2.53” | “1.955” |
| 100 mg once daily | “4” | “9.73” | “2.842” | “1.34” | “0.948” |
| 200 mg once daily | “3” | “2.51” | “3.681” | “3.01” | “2.955” |
| 400 mg once daily | “5” | “4.92” | “10.240” | “2.71” | “2.232” |
| 600 mg once daily | “3” | “6.59” | “4.229” | “1.19” | “2.067” |
Disease response, progression, and leukemic transformation in MDS, posted results
Percentage change in hepcidin and trough concentration, posted results
| Group | Hepcidin: participants analyzed | Mean percent change in hepcidin, Cycle 1 Day 15 to Cycle 7 Day 1 | Standard deviation | Mean Ctrough (nanomolar) | Standard deviation |
|---|---|---|---|---|---|
| 50 mg once daily | “4” | “-24.53” | “41.69” | “214” | “91.8” |
| 100 mg once daily | “4” | “-16.25” | “47.06” | “304” | “175” |
| 200 mg once daily | “4” | “-11.25” | “39.97” | “619” | “241” |
| 400 mg once daily | “5” | “-59.02” | “32.35” | “981” | “3130” |
| 600 mg once daily | “3” | “-63.79” | “44.23” | “NA” | “NA” |
Pharmacokinetic values not determined at 600 mg
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Primary safety outcomes by dose group, posted results
Maximum tolerated dose and recommended dose for expansion not determined
Serious adverse events and all-cause mortality by dose group, posted results
| Group | Serious adverse events, affected/at risk (%) | All-cause mortality, affected/at risk (%) |
|---|---|---|
| 50 mg once daily | “2/4 (50.00%)” | “1/4 (25.00%)” |
| 100 mg once daily | “1/5 (20.00%)” | “1/5 (20.00%)” |
| 200 mg once daily | “2/4 (50.00%)” | “0/4 (0.00%)” |
| 400 mg once daily | “2/5 (40.00%)” | “1/5 (20.00%)” |
| 600 mg once daily | “0/3 (0.00%)” | “0/3 (0.00%)” |
| Total | “7/21 (33.33%)” | “3/21 (14.29%)” |
Serious adverse events in more than 1 participant
| Serious adverse event | Affected/at risk (%) |
|---|---|
| Anaemia | “2/21 (9.52%)” |
| COVID-19 | “2/21 (9.52%)” |
Nonserious adverse events in 3 or more of 21 participants, and events listed in the FOP label
| Adverse event | Affected/at risk (%) |
|---|---|
| Oedema peripheral | “6/21 (28.57%)” |
| Fatigue | “4/21 (19.05%)” |
| Nausea | “4/21 (19.05%)” |
| Urinary tract infection | “4/21 (19.05%)” |
| Abdominal pain | “3/21 (14.29%)” |
| Alopecia | “3/21 (14.29%)” |
| Amylase increased | “3/21 (14.29%)” |
| Constipation | “3/21 (14.29%)” |
| Diarrhoea | “3/21 (14.29%)” |
| Dizziness | “3/21 (14.29%)” |
| Dyspnoea | “3/21 (14.29%)” |
| Electrocardiogram QT prolonged | “3/21 (14.29%)” |
| Hyperphosphataemia | “3/21 (14.29%)” |
| Pruritus | “3/21 (14.29%)” |
| Epistaxis | “1/21 (4.76%)” |
| Arthralgia | “1/21 (4.76%)” |
| Serum ferritin increased | “1/21 (4.76%)” |
Adverse event collection period and population
Study limitations
Summary: limitations for a formulary review of zilurgisertib in fibrodysplasia ossificans progressiva
LIMBER-105 was terminated for a strategic business decision after enrolling 22 participants, of whom 21 were treated and analyzed. No participants with multiple myeloma were enrolled, so all results come from participants with MDS or MDS/MPN overlap syndromes, with a mean age of 74.4 years. The study was open-label, single-arm, and without a control group, with 2 to 5 participants per dose level (50 mg to 600 mg once daily for up to 6 months). The expansion stage enrolled no participants, the maximum tolerated dose could not be determined because the stopping rule was not met, and the recommended dose for expansion was not established. The SAP defines all analyses as exploratory. No peer-reviewed publication or congress abstract of the results was identified, and no health-related quality of life or patient-reported outcome results were reported.
INCB 00928-101 single ascending dose and food effect study in healthy participants
Objective
Safety, pharmacokinetic, and food effect objectives
“The objectives of these studies were to evaluate zilurgisertib pharmacokinetics, safety, tolerability, and the effect of food in healthy participants from phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A further primary objective of the SAD study was determination of the effect of food on zilurgisertib pharmacokinetics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiac safety objective of the pooled concentration-QTc analysis
“The objective of this analysis was to evaluate the effect of zilurgisertib on QT intervals using a model based approach, as well as to assess other electrocardiogram (ECG) parameters, based on PK and ECG data collected during the phase 1 SAD and MAD studies in healthy adult participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study sites and dosing period
Study design
Randomized, double-blind, placebo-controlled first-in-human design
“These were phase 1, randomized, double-blind (participants and investigators blinded, sponsor unblinded), placebo-controlled studies to determine safety, tolerability, and pharmacokinetics associated with single ascending doses (SAD) or multiple ascending doses (MAD) of oral zilurgisertib in healthy adults.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The SAD was a multicenter study, and the MAD was a single-center study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Two-part design with a crossover food effect cohort
“The SAD study (INCB 00928-101) was composed of 2 parts. In part 1, tolerability and pharmacokinetics of zilurgisertib were assessed under fasted conditions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cohort 8 was to explore a single to-be-decided dose (e.g., if a dose level needed to be repeated, alternate dosing regimens explored, or further dose escalation allowed to proceed); this cohort was optional and not enrolled.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 12 healthy adult participants were enrolled into cohort 9 and randomized to receive a single oral dose of zilurgisertib 100 mg, after either an overnight fast or a high-fat meal, in a 2-way crossover manner with a 7-day washout period between drug administrations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Continuous Holter electrocardiogram monitoring
“ECG was performed continuously from 4 hours pre dose to 24 hours post dose on day 1 (all cohorts) and day 8 (cohort 9 only) in the SAD study, and from 4 hours pre dose through 24 hours post dose on days 1 and 10 in the MAD study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Healthy adults aged 18 to 55 years
“Eligible participants were men and women, 18–55 years of age, with a body mass index between 18 and 30 kg/m2, assessed to be in good health based on their medical history and physical examinations, including vital signs, electrocardiogram (ECG), and clinical laboratory test results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Applicants with hemoglobin levels and white blood and platelet counts below the lower reference limit for the parameters were excluded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Use of any medications known to affect cytochrome P450 enzymes or P-glycoprotein activity was prohibited within 30 days or 5 half-lives (whichever was longer) before study start and throughout the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Single oral doses of 10 to 500 mg or placebo
“Healthy adult participants were enrolled in 7 cohorts at dose levels of 10, 25, 50, 100, 175, 250, and 500 mg and were randomized to receive either a single dose of zilurgisertib or placebo, both in tablet form, in an approximately 3:1 ratio.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both studies used a tablet formulation of the study drug, with doses comprising 5-mg or 25-mg tablets.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using adverse events and plasma pharmacokinetic parameters as the primary endpoints
Safety and pharmacokinetic primary objectives
“The primary objectives of both studies included determination of safety and tolerability of zilurgisertib, in either single (SAD study) or multiple (MAD study) ascending doses, as assessed by monitoring the frequency and severity of adverse events (AEs), physical examinations, vital signs, 12-lead ECGs, telemetry, and analysis of clinical laboratory data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additional primary objectives were analysis of zilurgisertib pharmacokinetics following administration in the fasting state after either a single dose (SAD study) or multiple escalating doses (MAD study).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary urine and exploratory saliva pharmacokinetic endpoints
“Secondary objectives of both studies were the characterization of additional plasma pharmacokinetic parameters, including apparent terminal half-life (t½), apparent oral dose clearance (CL/F), apparent oral dose volume of distribution (Vz/F), and apparent terminal elimination constant (ke), as well as urine pharmacokinetic parameters including amount of drug excreted in urine over 96 h (Ae0-96h; MAD study) or 144 h (SAD study) and renal clearance (CLR).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Exploratory objectives of both studies included analysis of preliminary salivary pharmacokinetics, including salivary clearance after single or multiple doses of zilurgisertib in the SAD and MAD studies, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Saliva sampling as an alternative matrix for people with FOP
“Saliva is an attractive alternative to blood for drug monitoring and pharmacokinetic analysis, as it is non-invasive to retrieve. This is beneficial for patients, such as those with FOP, for whom blood draws can be challenging due to soft tissue damage susceptibility that can cause progressive heterotopic ossification, and for whom tourniquet time and blood draws must be minimized.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Saliva bioanalytical method for zilurgisertib
“Incurred sample reanalysis (ISR) using a successfully validated method failed in a healthy volunteer study because of inhomogeneous INCB000928 concentration across sample tube depths. Individual mixing of sample tubes followed by immediate aliquoting corrected the ISR failure, with 97.2% of repeats passing versus 41.7% for the same ISR samples.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Individualized QT correction as the primary cardiac endpoint
“As both studies indicated a dose‐dependent effect of zilurgisertib on heart rate, individualized QT correction (QTcI) was used as the primary endpoint for QTc analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given the results of the present analysis, the waiver for thorough QT study has been approved by the FDA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Food effect cohort as the ECG assay sensitivity control
“The effect of food on QTc was used to demonstrate ECG assay sensitivity, because administration of food shortens the QTc by 5‐10 ms, with the maximum effect occurring approximately 2‐4 hours after a meal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned cohort size and its basis
“All cohorts were to have approximately 12 participants (9 participants in each cohort receiving zilurgisertib and 3 receiving matching placebo).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cohort sample sizes were determined empirically and not derived from statistical power calculations, per other initial safety and tolerability studies of a similar nature” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants randomized and analyzed
“Overall, 91 participants (70 active, 21 placebo) were enrolled and randomized to the SAD study and 79 participants (59 active, 20 placebo) were enrolled and randomized to the MAD study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ninety-one participants were included in the safety population and 70 participants were included in the pharmacokinetic population (58 in cohorts 1–7 and 12 in cohort 9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Safety and pharmacokinetic-evaluable populations
“The safety population included all randomized participants who received ≥ 1 dose of zilurgisertib or placebo. Treatment groups were determined per protocol. The pharmacokinetic-evaluable population included all participants who received ≥ 1 dose of zilurgisertib and provided ≥ 1 post-dose plasma pharmacokinetic sample.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose proportionality and food effect analyses
“Dose proportionality of zilurgisertib was assessed by a power model that regresses the natural log-transformed pharmacokinetic parameters (Cmax, AUC0-t, AUC0-inf, and AUC0-tau, as deemed appropriate) against the natural log-transformed doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Food effect on plasma pharmacokinetics after a single dose of zilurgisertib 100 mg was evaluated by ANOVA using a mixed-effects model with fast/fed status, sequence, and period as fixed effects and participant as a random effect fitted to the log-transformation of plasma exposures (Cmax, AUC0-t, and AUC0-inf).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
QT/QTc and PK/QTc populations
“Categorical and central tendency analyses were conducted in the QT/QTc population, comprising all participants in the safety population with continuous ECG measurements at baseline and on treatment. The C‐QTc analysis was conducted in the PK/QTc population, which comprised all participants who were in the QT/QTc population and the PK‐evaluable population plus participants treated with placebo with at least one pair of time‐matched post‐baseline PK and QTc data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The PK/QTc data from cohort 9 of the SAD study (12 participants fed with high‐fat meals) were excluded from the ECG central tendency analysis and the primary C‐QTc analysis but were analyzed in the sensitivity analysis of food effects on QTc shortening.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Allocation by cohort and completion
“Nine participants each were allocated to the 10-, 25-, 50- (cohorts 1–3), 175-, and 250-mg (cohorts 5, 6) fasted groups; 7 to the 100-mg (cohort 4) fasted group; and 6- to the 500-mg (cohort 7) fasted group. Twelve participants were allocated to the 100-mg fasted and fed group (cohort 9) and 21 patients in total received placebo. Ninety participants completed the study. One participant from the 100-mg fasting cohort completed treatment but was lost to follow-up on day 7.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Sex, age, and body mass index
“Overall, 64% of participants in the SAD study and 67% in the MAD study were male. Mean [standard deviation (SD)] age of participants was 36.1 (9.2) years and 35.3 (8.4) years and mean (SD) body mass index was 25.8 (2.8) kg/m2 and 26.4 (2.5) kg/m2 in the SAD and MAD studies, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sex distribution reported in the cardiac safety analysis
“Overall, 91 participants in the SAD study and 79 participants in the MAD study provided at least one pair of zilurgisertib PK and ECG data. In the SAD study, most participants (63.7%) were female, whereas in the MAD study, the majority (67.1%) were male” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Single-dose plasma pharmacokinetics under fasting conditions
Absorption, half-life, and dose proportionality
“Zilurgisertib was absorbed rapidly at all dose levels. Median plasma tmax ranged from 2.0 to 4.1 h and was 2 h with doses ≥ 100 mg, the proposed clinically relevant dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Geometric mean t½ was consistent across all 7 dose levels [range, 23.1 (10-mg cohort) to 31.4 h (175-mg cohort)] and overall geometric mean t½ was 27.8 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The exponents on dose from the power function regression were 1.1 for Cmax, AUC0-t, and AUC0-inf, and 90% CIs excluded unity in all cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Food effect: single 100 mg dose, fasted and after a high-fat meal
| Condition | n | Cmax, geometric mean (geometric %CV), nM | tmax, median (range), h | AUC0-inf, geometric mean (geometric %CV), h·nM |
|---|---|---|---|---|
| 100 mg fasted | “12”View highlighted excerpt for this quote | “392 (27%)”View highlighted excerpt for this quote | “3.0 (2.0–5.0)”View highlighted excerpt for this quote | “9090 (22%)”View highlighted excerpt for this quote |
| 100 mg fed | “12”View highlighted excerpt for this quote | “383 (19%)”View highlighted excerpt for this quote | “4.0 (1.0–5.0)”View highlighted excerpt for this quote | “9370 (20%)”View highlighted excerpt for this quote |
Geometric mean ratios for fed versus fasted administration
“Median tmax was not significantly different with and without food (4 h versus 3 h; p = 0.2788). ANOVA analysis of Cmax, AUC0-t, and AUC0-inf also showed no significant impact of food, sequence, or period on the pharmacokinetics of single dose administration of zilurgisertib. GMRs (90% CI) for Cmax, AUC0-t, and AUC0-inf were 0.98 (0.91–1.06), 1.03 (0.97–1.10), and 1.03 (0.97–1.10), respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Label statement on absorption and food effect
Renal clearance after a single dose
“Renal clearance was similar across all dose levels in both studies. Geometric mean CLR was 3.6 L/h with single doses, and 4.3 L/h with multiple doses. In the SAD study, CLR accounted for 18% of the total CL/F.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Saliva and plasma concentration correlation
“Strong correlation was seen between plasma and saliva zilurgisertib concentrations and exposure with both single (Supplementary Fig. S2) and multiple doses (Fig. 5); r2 values ranged from 0.9 to 1.0 in the SAD study and from 0.7 to 0.9 in the MAD study (Table 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Saliva zilurgisertib Cmax and AUC values were approximately 2.1- and 2.5-fold higher, respectively, with single doses and 3.1- and 2.7-fold higher with multiple doses than in plasma” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Treatment-emergent adverse events
“In total, TEAEs were reported for 28 participants (31%) during the SAD study [zilurgisertib, n = 23 (33%); placebo, n = 5 (24%)]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“TEAEs reported in the SAD study were similar across cohorts 1, 3, 4, 5, and 7 (range, 17–29%) and were possibly elevated in cohorts 2 (25 mg) and 6 (250 mg) (range, 44–67%). These differences should be interpreted with caution due to the small cohort sizes. TEAEs were similar between the fasted and fed participants in cohort 9 (1 participant, 8% vs. 3 participants, 25%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ten participants (11%) reported 14 treatment-related TEAEs (TRAEs) in the SAD study (all n = 1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serious adverse events, dose-limiting toxicities, and discontinuations
“No dose-limiting toxicities were observed and no deaths occurred during either study. No TEAEs led to study drug discontinuation, interruption, or reduction in the SAD study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One serious TEAE was reported in the SAD study (pneumonia, grade 3, beginning on study day 15 and considered unrelated to zilurgisertib); the participant required hospitalization before the pneumonia resolved on day 24. All other TEAEs across both studies were grade 1 or 2. No notable trends or treatment-emergent safety concerns emerged from clinical laboratory tests or monitoring of vital signs and 12-lead ECGs in either study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Heart rate and QTcI central tendency after single doses
“LSMs (90% CI) of ΔΔHR were higher than ±5 (1.84, 12.50) bpm at 6, 8, and 12 hours after study drug administration for the 500‐mg dose group in the SAD study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the SAD study, the highest upper limit of 90% CIs of the LSM ∆∆QTcI was 12.3 ms in the dose group of 250 mg at the 8 hours post treatment timepoint.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All participants except for 2 in the SAD study had baseline and post‐treatment PR ≤200 ms. There was no dose dependence in incidence of QRS >100 ms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concentration-QTc model pooled with the multiple ascending dose study
“The estimated population slope of the C‐ΔQTcI relationship was shallow at 0.02 ms per µm (standard error [SE], 0.319; 90% CI, −0.60, 0.65), which was not statistically significantly different from 0, and treatment effect–specific intercept was also small and non‐significant (−0.83 ms [SE, 0.728]; 90% CI, −2.26, 0.61).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At no dose level did the upper limit of the two‐sided 90% confidence band of the predicted QT effect exceed 5 ms across the observed range of zilurgisertib concentrations in this study (i.e. up to 7420 nm [or 3732 ng/mL]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ECG assay sensitivity in the food effect cohort
“In the assay sensitivity analysis by food effect (cohort 9 of the SAD study), estimated effects of a high‐fat breakfast on LSM (90% CI) of ΔQTcI were −11.7 (−15.59, −7.81) ms and −8.6 (−12.46, −4.76) ms at 2 and 4 hours post dose. Estimated 90% CIs for these effects were <0, and thus ECG assay sensitivity was considered to have been established.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: limitations of the single ascending dose study
The study enrolled 91 healthy adults aged 18 to 55 years with a body mass index of 18 to 30 kg/m2, so it provides no pharmacokinetic or safety data in people with fibrodysplasia ossificans progressiva or in participants younger than 18 years, although the labeled population begins at 12 years of age. Dose cohorts held 6 to 12 participants each, and cohort sizes were set empirically without power calculations; the authors state that the higher adverse event rates in the 25 mg and 250 mg cohorts should be interpreted with caution because of the small cohort sizes. The food effect was tested at one dose (100 mg) in 12 participants. Zilurgisertib increased heart rate in a dose-dependent manner, so the cardiac analysis replaced the planned Fridericia correction with an individualized correction; the concentration-QTc analysis pooled this study with the multiple ascending dose study and served in place of a thorough QT study. The two publications from this study report different sex distributions for the same 91 participants: 64% male in the pharmacokinetic report and 63.7% female in the cardiac safety report.
INCB 00928-102 multiple ascending dose study in healthy participants
Objective
Safety, tolerability, and pharmacokinetics after repeated dosing
Cardiac safety objective of the pooled concentration-QTc analysis
“The objective of this analysis was to evaluate the effect of zilurgisertib on QT intervals using a model based approach, as well as to assess other electrocardiogram (ECG) parameters, based on PK and ECG data collected during the phase 1 SAD and MAD studies in healthy adult participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study site and dosing period
Study design
Randomized, double-blind, placebo-controlled, single-center design
“These were phase 1, randomized, double-blind (participants and investigators blinded, sponsor unblinded), placebo-controlled studies to determine safety, tolerability, and pharmacokinetics associated with single ascending doses (SAD) or multiple ascending doses (MAD) of oral zilurgisertib in healthy adults.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The SAD was a multicenter study, and the MAD was a single-center study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ten-day dosing with a twice-daily cohort
“BID dosing was used to reduce the total number of tablets required to be taken by participants at one time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants received study medication for 10 days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Healthy adults aged 18 to 55 years
“Eligible participants were men and women, 18–55 years of age, with a body mass index between 18 and 30 kg/m2, assessed to be in good health based on their medical history and physical examinations, including vital signs, electrocardiogram (ECG), and clinical laboratory test results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Use of any medications known to affect cytochrome P450 enzymes or P-glycoprotein activity was prohibited within 30 days or 5 half-lives (whichever was longer) before study start and throughout the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Once-daily doses of 50 to 400 mg or 300 mg twice daily
“Healthy adult participants were enrolled in 6 cohorts (cohorts 1–5 up to 12 participants, cohort 6 up to 20 participants) at dose levels of 50, 100, 150, 200, and 400 mg once daily (QD) or 300 mg twice daily (BID) approximately 12 h apart, and were randomized to receive either zilurgisertib tablets or placebo tablets in an approximately 3:1 ratio.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using adverse events and plasma pharmacokinetic parameters as the primary endpoints
Safety and pharmacokinetic primary objectives
“The primary objectives of both studies included determination of safety and tolerability of zilurgisertib, in either single (SAD study) or multiple (MAD study) ascending doses, as assessed by monitoring the frequency and severity of adverse events (AEs), physical examinations, vital signs, 12-lead ECGs, telemetry, and analysis of clinical laboratory data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Plasma pharmacokinetic parameters were assessed via evaluation of maximum plasma drug concentration (Cmax), time to Cmax (tmax), area under the plasma concentration–time curve (AUC) from time 0 to the last measurable concentration at time t (AUC0-t) analyzed after the first dose of the study drug (single dose, both studies) and at steady state (MAD study only), AUC over the dosing interval (AUC0-tau; MAD study only), and AUC extrapolated to infinity (AUC0-inf; SAD study only).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Accumulation analysis
“Accumulation of plasma exposure on day 10 versus day 1 in the MAD study was evaluated using ANOVA on log-transformed pharmacokinetic parameters [Cmax, AUC0-24h (QD regimens), or AUC0-12h (BID regimen) on day 1, and Cmax and AUC0-tau on day 10].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Individualized QT correction as the primary cardiac endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants randomized and analyzed
“Overall, 91 participants (70 active, 21 placebo) were enrolled and randomized to the SAD study and 79 participants (59 active, 20 placebo) were enrolled and randomized to the MAD study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seventy-nine participants were included in the safety population; 59 of these received zilurgisertib and were included in the pharmacokinetic population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Safety and pharmacokinetic-evaluable populations
“The safety population included all randomized participants who received ≥ 1 dose of zilurgisertib or placebo. Treatment groups were determined per protocol. The pharmacokinetic-evaluable population included all participants who received ≥ 1 dose of zilurgisertib and provided ≥ 1 post-dose plasma pharmacokinetic sample.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only participants with pharmacokinetic data on both days 1 and 10 were included in the statistical analysis of accumulation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Completion and withdrawals
“Seventy-seven participants completed the study. Two participants from cohort 6 (300 mg BID) were withdrawn from the study due to treatment-emergent AEs (TEAEs); 1 participant was withdrawn after 5 doses of zilurgisertib (2.5 days of 300 mg BID dosing) due to hypersensitivity and 1 participant was withdrawn after single doses of zilurgisertib 300 mg on days 1 and 3 due to tachycardia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Sex, age, and body mass index
“Overall, 64% of participants in the SAD study and 67% in the MAD study were male. Mean [standard deviation (SD)] age of participants was 36.1 (9.2) years and 35.3 (8.4) years and mean (SD) body mass index was 25.8 (2.8) kg/m2 and 26.4 (2.5) kg/m2 in the SAD and MAD studies, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Day 10 steady-state plasma pharmacokinetics
Dose proportionality, half-life, and time to steady state
“Exponents (90% CIs) on dose from the power function regression were 1.1 (1.0–1.2) for both Cmax and AUC0-t following a single dose and 1.2 (1.1–1.3) and 1.2 (1.1–1.3) for Cmax and AUC0-24h, respectively, after multiple doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Plasma t½ geometric mean (range) was 25.2 h (22.8–27.5) and values were similar across all dose levels. Steady state was achieved by day 5.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Accumulation after repeated dosing
“Following multiple QD zilurgisertib dose administrations, geometric mean accumulation ratios (based on ANOVA) ranged from 1.7 to 2.1 and from 1.9 to 2.6, respectively, for Cmax and AUC with zilurgisertib QD, and were approximately 3.1 and 3.8, respectively, for plasma Cmax and AUC with zilurgisertib 300 mg BID.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Urinary excretion of unchanged drug
“Overall, geometric mean fraction of the total dose excreted in urine was 16% and 27% with single and multiple doses, respectively, showing that renal elimination of the parent molecule was not the predominant route.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Treatment-emergent and treatment-related adverse events
“32 participants (41%) during the MAD study [zilurgisertib, n = 27 (46%); placebo, n = 5 (25%)]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the MAD study, there was no clear dose-related trend in incidence or type of TEAEs reported across dose levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“14 participants (18%) reported TRAEs in the MAD study; [all n = 1, except palpitation [n = 2 (3%)], headache [n = 6 (8%)], nausea [n = 2 (3%)], and dizziness postural [n = 2 (3%)].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No dose-related trends were seen in incidence or types of TEAEs across doses, although incidence of TRAEs was slightly higher with the 300 mg BID dose versus the 50–400 mg QD doses in the MAD study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose interruptions and withdrawals
“In the MAD study, 1 participant experienced grade 1 TEAEs on days 1 and 2, leading to study drug being withheld on days 2 and 3. TEAEs were considered unrelated to the study drug by the investigator.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two participants withdrew from the MAD study due to TEAEs (tachycardia, n = 1; hypersensitivity, n = 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Heart rate and QTcI central tendency after repeated doses
“higher than ±5 (3.56, 9.36) bpm at 4 hours after administration on day 1 of the MAD study for the 300‐mg BID dose group; and at 4 and 6 hours after administration on day 10 of the MAD study for 300 mg BID dose group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On day 1 of the MAD study, the highest upper limit of 90% CIs of the LSM ∆∆QTcI was 17.4 ms in the dose group of 50 mg QD at the 16 hour post‐dosing timepoint; on day 10, the highest upper limit of 90% CIs of the LSM ∆∆QTcI was 16.4 ms in the dose group of 50 mg QD at the 16 hour post‐dosing timepoint.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Predicted QT effect at the highest exposure studied
“−0.71 ms (90% CI, −2.99, 1.57) at 4690 nm (or 2359 ng/mL), the highest observed geometric mean of peak zilurgisertib plasma concentrations after 300 mg BID” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean observed zilurgisertib plasma concentrations at 100 mg QD (0.61 µm [or 0.3 µg/mL]) are expected to be approximately 12‐fold lower than the highest concentration (7.4 µm [or 3.7 µg/mL]) studied in this analysis and thus no cardiac safety concerns are anticipated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A QT effect exceeding the threshold of concern (10 ms) can be excluded for zilurgisertib plasma concentrations up to 7.4 µm (or 3.7 µg/mL).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: limitations of the multiple ascending dose study
The study enrolled 79 healthy adults aged 18 to 55 years at a single United States site and dosed them for 10 days, so it does not describe exposure or safety over the long-term daily use intended in fibrodysplasia ossificans progressiva, or in participants younger than 18 years. Cohorts held 9 to 12 participants receiving zilurgisertib. Exposure rose more than dose-proportionally, with power-model exponents of 1.2 for Cmax and AUC0-24h after multiple doses. Two of the 79 participants, both in the 300 mg twice-daily cohort, withdrew for adverse events (tachycardia and hypersensitivity), and heart rate increased at that dose, so the cardiac analysis used an individualized QT correction. The concentration-QTc conclusions rest on pooled data from this study and the single ascending dose study.
Itraconazole and rifampin drug interaction study in healthy participants
Objective
Effect of a strong CYP3A inhibitor and a strong CYP3A4 inducer on zilurgisertib
“A drug-drug interaction study was conducted to evaluate the impact of the strong CYP3A inhibitor itraconazole and the strong CYP3A4 inducer rifampin on the pharmacokinetics of zilurgisertib in healthy participants.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study dates, site, and ethics approval
“This open-label, fixed-sequence, drug-drug interaction study was conducted between March 25, 2021, and May 18, 2021, at Altasciences (Cypress, CA, USA).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The protocol was approved by the Salus Institutional Review Board (Austin, TX, USA).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Study design
Two fixed-sequence cohorts in healthy participants
“Participants in Cohort 1 (n = 18) received zilurgisertib 100 mg on Days 1 and 10 and itraconazole 200 mg once daily on Days 6-13. Participants in Cohort 2 (n = 18) received zilurgisertib 100 mg on Days 1 and 13 and rifampin 600 mg once daily on Days 6-15.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for the zilurgisertib dose and fixed-sequence design
“Participants in both cohorts received zilurgisertib 100 mg, a dose 5 times lower than the maximum dose assessed in a previous Phase 1 study (INCB 009280-101), where no dose-limiting toxicities were observed and the maximum tolerated dose was not reached.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the current study, a dose of zilurgisertib 100 mg was selected to allow for the anticipated increase in exposure following coadministration with the strong CYP3A inhibitor itraconazole, and a reduction in exposure when coadministered with the potent CYP3A4 inducer rifampin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Inclusion and exclusion criteria
“Eligible participants were healthy adults aged 18-55 years” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“no significant findings on clinical, laboratory, and electrocardiogram (ECG) screening evaluations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were excluded if they had a history or clinical manifestations of significant metabolic, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, urologic, neurologic, or psychiatric disorders or any current or recent history of a clinically significant bacterial, fungal, parasitic, or mycobacterial infection or were currently receiving systemic antibiotics.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Zilurgisertib 100 mg alone and with itraconazole or rifampin
“Participants in Cohort 1 (n = 18) received zilurgisertib 100 mg on Days 1 and 10 and itraconazole 200 mg once daily on Days 6-13. Participants in Cohort 2 (n = 18) received zilurgisertib 100 mg on Days 1 and 13 and rifampin 600 mg once daily on Days 6-15.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using zilurgisertib maximum concentration and area under the curve as the primary endpoints
CYP3A4/5 as the primary elimination pathway
Statistical analysis description
Number of participants (Planned and analyzed)
Participants per cohort
“Participants in Cohort 1 (n = 18) received zilurgisertib 100 mg on Days 1 and 10 and itraconazole 200 mg once daily on Days 6-13. Participants in Cohort 2 (n = 18) received zilurgisertib 100 mg on Days 1 and 13 and rifampin 600 mg once daily on Days 6-15.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sample size set empirically, not by a power calculation
Description of analysis sets
Pharmacokinetic-evaluable and safety populations
“The PK-evaluable population included all participants who received at least 1 dose of the study drug and provided at least 1 measurable postdose PK blood sample.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The safety population included all participants who received at least 1 dose of study drug.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Enrollment, completion, and withdrawals by cohort
“A total of 38 participants were enrolled in the study (18 in Cohort 1 and 20 in Cohort 2). Thirty-five participants completed the study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One participant in Cohort 1 withdrew on Day 19 (participant withdrew consent).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Two participants in Cohort 2 withdrew; 1 withdrew on Day 11 (participant met a withdrawal criterion [noncompliance]) and 1 withdrew on Day 18 (due to treatment-related treatment-emergent AEs [TEAEs; abdominal pain and 2 episodes of vomiting]; participant discontinued treatment on Day 8).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Both these participants were replaced.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Age, sex, and body weight by cohort
“There were no apparent differences between the 2 cohorts with regard to age, sex, and race. The mean age was 37.2 years in Cohort 1 and 32.4 years in Cohort 2. Mean body weight was 80.4 kg in Cohort 1 and 78.0 kg in Cohort 2.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sixteen participants (89%) in Cohort 1 and 17 (85%) in Cohort 2 were men.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Change in zilurgisertib exposure with itraconazole and rifampin
“With the concomitant administration of itraconazole, the geometric mean maximum plasma drug concentration (Cmax) and area under the concentration-time curve from time 0 to infinity (AUC0-inf) of zilurgisertib increased by 1.28- and 2.13-fold, respectively. With the concomitant administration of rifampin, there was a 2.27- and 4.76-fold reduction in the geometric mean Cmax and AUC0-inf of zilurgisertib, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Zilurgisertib dose adjustment may be necessary with concomitant administration of strong CYP3A4 inhibitors, and coadministration of zilurgisertib with strong CYP3A4 inducers is not recommended.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Additional exposure parameters: AUC0-t, clearance, and half-life
“Coadministration of zilurgisertib with itraconazole significantly increased geometric mean Cmax, AUC0-t, and AUC0-inf by 1.28-, 2.17-, and 2.13-fold, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Coadministration with itraconazole decreased geometric mean CL/F by 2.13-fold” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“a 2.27-fold decrease in geometric mean Cmax and a 4.76-fold decrease in both AUC0-t and AUC0-inf were observed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Coadministration with rifampin increased geometric mean CL/F by 4.88-fold” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Label statement of the interaction results and resulting dosing instructions
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Adverse event incidence, discontinuations, and clinical monitoring
“Nine participants (24%) reported at least 1 TEAE during the study (Cohort 1, 4 participants [22%] reported a total of 5 TEAEs [salivary gland mucocele, corneal abrasion, psoriasis, headache, n = 1 participant each; 1 participant experienced 2 incidences of headache]; Cohort 2, 5 participants [25%] reported a total of 8 TEAEs [vomiting, urticaria, skin abrasion, allergic rhinitis, n = 1 participant each; mild abdominal pain, n = 2 participants; 1 participant experienced 3 TEAEs (mild abdominal pain and 2 incidences of vomiting), 1 participant experienced 2 TEAEs (2 incidences of urticaria)]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although 1 participant discontinued rifampin due to a TEAE of vomiting, no TEAEs led to the discontinuation of zilurgisertib.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There were no safety concerns based on clinical laboratory results, vital signs, or 12-lead ECGs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There were no serious TEAEs or deaths reported in the study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: limitations of the drug interaction study
Each cohort enrolled 18 healthy adults and used an open-label, fixed-sequence design in which zilurgisertib 100 mg was given alone and then with itraconazole or rifampin, so each participant served as their own control rather than being randomized to a comparator arm. The study tested a single zilurgisertib dose of 100 mg, one-fifth of the highest dose evaluated in earlier phase 1 studies, together with a single regimen of one strong CYP3A4 inhibitor (itraconazole 200 mg once daily) and one strong CYP3A4 inducer (rifampin 600 mg once daily); the label's statements on moderate CYP3A4 inhibitors, moderate CYP3A4 inducers, and CYP2D6 inhibitors remain model predictions rather than results of a clinical study, and the full-text discussion notes that more potent strong CYP3A4 inhibitors than itraconazole could produce a larger increase in zilurgisertib exposure than observed here. Sample size for each cohort was set empirically, following precedent from similar studies, rather than by a statistical power calculation, and two participants in the rifampin cohort discontinued before the second treatment period and were replaced. The study enrolled healthy adults rather than participants with fibrodysplasia ossificans progressiva, and the reason for the variability in interaction magnitude observed across participants was not determined. The cardiac safety publication cites a 2.5-fold increase in AUC under strong CYP3A inhibition, which differs from the 2.13-fold increase in AUC0-inf reported by this study and by the label.
INCB 00928-108 renal impairment study
Objective
Effect of renal impairment and hemodialysis on zilurgisertib pharmacokinetics
“Here are the results of two separate Phase I, open‐label, parallel‐group studies (INCB 00928‐108; INCB 00928‐109) assessing the effect of renal and hepatic impairment, respectively, on zilurgisertib exposure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Registry status and dates
| Registry field | Quoted record |
|---|---|
| Sponsor protocol number | “INCB 00928-108” |
| Overall status | “Completed” |
| Start date, actual | “2021-12-14” |
| Primary completion, actual | “2023-02-19” |
| Study completion, actual | “2023-02-27” |
| Enrollment, actual | “48” |
Study design
Open-label, parallel-group design with matched controls
“Participants with normal renal or hepatic function, were enrolled and matched on a 1:1 basis with participants with impaired renal/hepatic function respectively, according to age (±10 years), sex and body mass index (±20%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Renal function groups assigned by estimated glomerular filtration rate
“Renal function was assessed at screening (2–28 days before administration of zilurgisertib) based on estimated glomerular filtration rate (eGFR) score, calculated via the isotope dilution mass spectrometry (IDMS)‐traceable 4‐variable Modification of Diet in Renal Disease (MDRD‐4‐IDMS) formula, and on the requirement for haemodialysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dosing before and after hemodialysis in end-stage renal disease
“Group 5 participants were admitted on two separate occasions. During their first visit, zilurgisertib was administered per Groups 1–4 and 3 h before the start of haemodialysis. Blood and dialysate samples were collected during the 4‐day stay in the unit following dosing. On visit 2 (5–7 days after the end of their first visit), zilurgisertib was administered 1 h after the end of haemodialysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Inclusion criteria
Treatment
Single 200 mg oral dose
“Zilurgisertib was administered as a single 200‐mg dose (8 × 25 mg tablets) in both studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following an 8‐h fast, Groups 1–4 participants received a single 200 mg oral dose in the morning of Day 1 and were confined to the unit for 4 days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using plasma cmax, AUC0-t, and AUC0-inf as the primary endpoints
Renal impairment can alter exposure to drugs cleared by non-renal pathways
“The potential impact of renal impairment on the PK of drugs cleared by non‐renal pathways (including intestinal and hepatic drug metabolism and transport) is well established.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As such, drugs with minimal renal clearance may still need dose adjustments in individuals with renal impairment, as reflected in current US Food and Drug Administration (FDA) guidance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Choice of the MDRD equation for group assignment
“was selected because, of the three standard methods available (MDRD‐4‐IDMS, Cockroft‐Gault and Chronic Kidney Disease Epidemiology Collaboration [CKD‐EPI]), it shows the greatest accuracy in estimation of renal clearance across difference stages of renal impairment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Truncated AUC as a supporting exposure measure
“Recent guidance from the US Food & Drug Administration supports the use of truncated AUCs (e.g., AUC0–72) as the primary exposure metrics for IR drugs with long half‐lives.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, AUC0–72 represents a robust and interpretable measure of systemic exposure across renal function groups; AUC0–∞ should be interpreted with caution in this population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hemodialysate bioanalytical method
“INCB000928 in hemodialysate exhibited strong nonspecific binding to polypropylene containers. In the presence of 10% isopropyl alcohol, the loss of INCB000928 was fully recovered, regardless of pre- or post-addition of the solvent.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned group sizes and their basis
“Up to eight participants could be enrolled into each renal/hepatic impairment group, to allow six or more participants per group to complete the study. The normal renal/hepatic function groups could consist of ≤ 16 participants. The sample size for these respective cohorts was based upon other PK studies of a similar nature and was not based on power calculations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants enrolled by renal function group
“Forty‐eight participants were enrolled in the renal impairment study: normal renal function n = 16; mild impairment n = 7; moderate impairment n = 8; severe impairment n = 8; end‐stage renal disease (ESRD) n = 9.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Safety and pharmacokinetic populations
Matched comparison by analysis of variance
“To evaluate the effect of renal/hepatic impairment on zilurgisertib PK, log‐transformed PK parameters (Cmax, AUC0–t, AUC0–∞) were compared between participants with renal/hepatic impairment and matched participants with normal renal/hepatic function using a one‐way analysis of variance (ANOVA) with a fixed factor for renal/hepatic function group and a random factor for participant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Summary statistics are presented for both excluding (n = 6) and including (n = 7) one participant with mild renal impairment who lacked a healthy‐matched participant with normal renal function. This participant was excluded from the ANOVA test.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Completion and exclusion from the pharmacokinetic population
“All participants completed the study and were included in the safety population; one participant with ESRD was excluded from the PK population because zilurgisertib was mistakenly administered before haemodialysis during their second visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Demographics and renal function by group
Efficacy results
Geometric mean ratios versus matched participants with normal renal function
| Renal function group | Cmax GMR (90% CI) | AUC0-inf GMR (90% CI) |
|---|---|---|
| Mild impairment | “0.92 (0.64–1.34)”View highlighted excerpt for this quote | “0.98 (0.77–1.24)”View highlighted excerpt for this quote |
| Moderate impairment | “1.22 (0.92–1.63)”View highlighted excerpt for this quote | “1.64 (1.28–2.10)”View highlighted excerpt for this quote |
| Severe impairment | “1.00 (0.74–1.35)”View highlighted excerpt for this quote | “1.70 (1.33–2.16)”View highlighted excerpt for this quote |
| ESRD, dosed before hemodialysis | “1.17 (0.91–1.49)”View highlighted excerpt for this quote | “1.47 (1.15–1.88)”View highlighted excerpt for this quote |
| ESRD, dosed after hemodialysis | “1.32 (1.00–1.75)”View highlighted excerpt for this quote | “1.68 (1.29–2.19)”View highlighted excerpt for this quote |
Half-life and apparent clearance in moderate and severe renal impairment
“Zilurgisertib plasma exposure was 45% higher in participants with moderate renal impairment versus normal renal function when determined by AUC0–t (GMR: 1.45, p = 0.0073) and 64% higher based on AUC0–∞ (GMR: 1.64, p = 0.0031); geometric mean terminal t½ (35.6 vs. 25.1 h, p = 0.0031; Table 2) was longer and geometric mean CL/F (12.3 vs. 20.2 L/h, p = 0.0031) was lower in participants with moderate renal impairment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Geometric mean terminal t½ (39.0 vs. 26.4 h, p = 0.0376; Table 2) was longer and geometric mean CL/F (11.0 vs. 18.7 L/h, p = 0.0017) was lower in participants with severe renal impairment, compared with those with normal renal function.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
End-stage renal disease and timing of hemodialysis
“Overall, changes in zilurgisertib exposure in participants with ESRD were similar to those seen in participants with moderate and severe renal impairment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Exposure was also increased by 30%–68% in participants with ESRD; notably, comparison of data obtained before and after haemodialysis demonstrate that zilurgisertib PK was not affected by the timing of dosing relative to this procedure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Renal and dialysate clearance
“In participants with normal renal function, the GMR of renal clearance of zilurgisertib was 4.4 L/h, dropping to 3.9, 2.1 and 1.4 L/h in participants with mild, moderate and severe renal impairment, respectively. Similarly, the fraction of dose eliminated in urine as unchanged drug dropped from 19% in participants with normal renal function to 18%, 12% and 9% in participants with mild, moderate and severe renal impairment, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The geometric mean dialysate clearance among participants with ESRD was 1.3 L/h and the geometric mean fraction excreted in dialysate was 1.0%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasma protein binding across renal function groups
Label statement of renal impairment results
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Treatment-emergent adverse events in the renal impairment study
“Overall, all TEAEs were of Grade 1 or 2 severity and resolved before the end of the studies; no serious or fatal TEAEs were observed. In the renal impairment study, five TEAEs occurred in three of 48 participants (6%), with four TEAEs in two participants with normal renal function considered treatment‐related by the study investigators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The second participant reported a treatment‐related TEAE of alopecia (Grade 1) on Day 5, which resolved by Day 7 without treatment. One participant with severe renal impairment experienced skin abrasion (Grade 1) that was not considered treatment‐related.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: limitations of the renal impairment study
The study gave one 200 mg dose to 48 adults with a median age of 54.0 to 72.5 years across groups, with 7 to 16 participants per group; group sizes were not based on power calculations, and it does not describe steady-state exposure at the 100 mg daily dose or exposure in adolescents. One participant with mild impairment had no matched control and was excluded from the comparison, and one participant with end-stage renal disease was excluded from the pharmacokinetic population after a dosing error. In moderate or worse impairment, sampling to 72 hours covered less than two half-lives, and the authors state that AUC0-inf should be interpreted with caution in this population. The label reports the 64% to 70% increases in AUC0-inf in its pharmacokinetics section and gives no dose adjustment for renal or hepatic impairment; the authors note that dosing recommendations were to be informed by the therapeutic index from the pivotal trial. The publication reports four renal study sites, while the registry record lists five locations.
INCB 00928-109 hepatic impairment study
Objective
Effect of hepatic impairment on zilurgisertib pharmacokinetics
“Here are the results of two separate Phase I, open‐label, parallel‐group studies (INCB 00928‐108; INCB 00928‐109) assessing the effect of renal and hepatic impairment, respectively, on zilurgisertib exposure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study design
Open-label, parallel-group design with matched controls
“Participants with normal renal or hepatic function, were enrolled and matched on a 1:1 basis with participants with impaired renal/hepatic function respectively, according to age (±10 years), sex and body mass index (±20%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Child-Pugh groups and the omitted mild impairment cohort
“Hepatic function was assessed at screening (2–28 days before zilurgisertib administration) based on Child–Pugh score, then reassessed for consistency on the day of admission before dosing. Participants with normal hepatic function were assigned to Group 4, those with severe hepatic impairment (Child–Pugh score of 10–14 points) to Group 1, and those with moderate impairment (7–9 points) to Group 2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following a pre‐specified interim analysis of PK results, it was determined that an additional cohort with mild hepatic impairment (Group 3; 4–6 points) was unnecessary as zilurgisertib exposure was similar between participants with normal and moderate hepatic impairment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Age, body mass index, and excluded conditions and medications
“Eligible participants were adults (18–82 years, renal impairment study, 18–80 years, hepatic impairment study), with body mass index of 18–40 and 18–44 kg/m2 in the renal and hepatic impairment studies, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In both studies, participants with unstable or clinically significant comorbidities were excluded” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Use of medications known to be potent inhibitors or potent/moderate inducers of CYP3A4 (hepatic study) and medications known to affect CYP3A4 or P‐glycoprotein (renal study) for the longer of 30 days or five half‐lives prior to dosing was prohibited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Single 200 mg oral dose
“Zilurgisertib was administered as a single 200‐mg dose (8 × 25 mg tablets) in both studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants refrained from food for 8 h before and 4 h after dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using plasma cmax, AUC0-t, and AUC0-inf as the primary endpoints
Pharmacokinetic parameters derived in both studies
“For both studies, the following PK parameters were calculated: maximum plasma drug concentration (Cmax); area under the plasma or serum concentration–time curve from time 0 to the last measurable concentration at time t (AUC0–t); total AUC extrapolated to infinity (AUC0–∞)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic clearance as the basis for a hepatic impairment study
“Similarly, plasma exposure can be influenced by liver diseases via altered hepatic metabolism/biliary excretion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PK studies should also be performed in patients with hepatic impairment where the condition is likely to significantly alter the PK of the drug and/or its metabolites, e.g., where hepatic metabolism/excretion accounts for >20% of the elimination of the parent/metabolite absorbed drug, and for drugs that may have a narrow therapeutic index.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned group sizes and their basis
“Up to eight participants could be enrolled into each renal/hepatic impairment group, to allow six or more participants per group to complete the study. The normal renal/hepatic function groups could consist of ≤ 16 participants. The sample size for these respective cohorts was based upon other PK studies of a similar nature and was not based on power calculations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants enrolled by hepatic function group
Description of analysis sets
Safety and pharmacokinetic populations
“All participants who received zilurgisertib were included in the safety population; those with at least one measurable PK sample collected were included in the PK population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To evaluate the effect of renal/hepatic impairment on zilurgisertib PK, log‐transformed PK parameters (Cmax, AUC0–t, AUC0–∞) were compared between participants with renal/hepatic impairment and matched participants with normal renal/hepatic function using a one‐way analysis of variance (ANOVA) with a fixed factor for renal/hepatic function group and a random factor for participant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Baseline characteristics
Demographics and liver function by group
Efficacy results
Geometric mean ratios versus matched participants with normal hepatic function
Moderate hepatic impairment
“GMRs for zilurgisertib exposure among participants with normal hepatic function versus those with moderate hepatic impairment were 1.06, 1.09 and 1.13 for Cmax, AUC0–t and AUC0–∞, respectively, with 90% CIs including unity for all parameters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Severe hepatic impairment
“Zilurgisertib plasma AUC0–t and AUC0–∞ were 22% and 25% higher in participants with severe hepatic impairment, respectively, than in participants with normal hepatic function. Cmax was similar in participants with severe hepatic impairment and those with normal hepatic function (GMR: 1.36, p = 0.0585). Lower geometric mean CL/F (16.0 vs. 20.1 L/h, p = 0.0347) and earlier median tmax (1.0 vs. 2.0 h, p = 0.0208) were observed in participants with severe hepatic impairment versus normal hepatic function.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Label statement of hepatic impairment results
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Treatment-emergent adverse events in the hepatic impairment study
“In the hepatic impairment study, four TEAEs occurred in two of 28 participants (7.1%) none of which were considered treatment‐related. One participant with severe hepatic impairment experienced TEAEs of vomiting (Grade 1) and nausea (Grade 2), and one participant with moderate hepatic impairment reported TEAEs of diarrhoea and headache (both Grade 1); all TEAEs resolved on the day of onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: limitations of the hepatic impairment study
The study gave one 200 mg dose to 28 adults (12 with normal hepatic function, 9 with moderate impairment, and 7 with severe impairment), with group sizes not based on power calculations. The mild impairment group was not enrolled after an interim analysis found similar exposure with moderate impairment, so no exposure data exist for mild hepatic impairment. The study describes neither steady-state exposure at the 100 mg daily dose nor exposure in adolescents. No registry record or study dates were located for this study.
Radiolabeled zilurgisertib mass balance study
Objective
No evidence found.
Location and study date
No evidence found.
Study design
No evidence found.
Eligibility criteria
No evidence found.
Treatment
Single oral 400 mg dose of radiolabeled zilurgisertib
Study outcomes
Rationale for using recovery of administered radioactivity as the primary endpoint
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Recovery of the dose in feces and urine
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
No evidence found.
Study limitations
Summary: limitations of the mass balance evidence
The only public evidence of this study is one sentence of the prescribing information, which reports recovery of 49% of a single 400 mg radiolabeled dose in feces and 38.5% in urine, for a total of 87.5%. No publication or registry record was located, so the population, number of participants, dates, and safety results are unknown. The label's 28% of the dose excreted unchanged in urine is close to the 27% fraction excreted unchanged in urine after multiple doses in the multiple ascending dose study.